Fidia S.p.A. (BIT:FDA)
0.1160
-0.0003 (-0.26%)
At close: Jan 30, 2026
Fidia Revenue
Fidia had revenue of 13.59M EUR in the half year ending June 30, 2025, with 51.15% growth. This brings the company's revenue in the last twelve months to 21.13M, down -28.94% year-over-year. In the year 2024, Fidia had annual revenue of 17.53M, down -38.98%.
Revenue (ttm)
21.13M
Revenue Growth
-28.94%
P/S Ratio
0.08
Revenue / Employee
150.93K
Employees
140
Market Cap
1.73M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 17.53M | -11.20M | -38.98% |
| Dec 31, 2023 | 28.74M | 4.07M | 16.52% |
| Dec 31, 2022 | 24.66M | 485.00K | 2.01% |
| Dec 31, 2021 | 24.18M | 2.52M | 11.65% |
| Dec 31, 2020 | 21.65M | -24.55M | -53.13% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| EuroGroup Laminations | 843.61M |
| Biesse | 676.33M |
| SIT S.p.A. | 314.71M |
| Tesmec | 252.11M |
| ILPRA | 80.39M |
| Clabo | 58.10M |
| OSAI Automation System | 41.92M |
| Marzocchi Pompe | 37.06M |
Fidia News
- 19 hours ago - Lilly's $3.5B manufacturing facility in PA to produce next-gen GLP-1 that promises “even more weight loss” - CNBC
- 1 day ago - Corcept Therapeutics (CORT) Shares Drop After FDA Feedback - GuruFocus
- 1 day ago - Regeneron outlines 18 new Phase III studies and expects four FDA approvals in 2026 while advancing EYLEA HD and DUPIXENT growth - Seeking Alpha
- 1 day ago - Analysts Maintain Bull Case On ResMed Despite Competition Concerns - Benzinga
- 1 day ago - New FDA-Approved Eye Drop Sparks Fresh Competition For LENZ Therapeutics' Drug - Benzinga
- 1 day ago - 5 Stocks Primed for a Turnaround in 2026 - Benzinga
- 1 day ago - Regeneron Posts Lower Eylea Sales Amid Rising Competition, Plans $2 Billion New Factory - Benzinga
- 1 day ago - Corcept Therapeutics (CORT) Stock Falls After FDA Rejects Drug Application - GuruFocus